Free tool · No account
Clinical trials for lung cancer
Many lung cancer trials are keyed to a specific mutation (EGFR, ALK, KRAS, ROS1, and others) rather than to the cancer alone. Knowing the tumor's biomarker often surfaces studies you would otherwise miss.
2,147 recruiting trials. Showing a sample.
- recruitingNANCT07608835
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to charac...
Listed by the study for Non-small Cell Lung Cancer. Record updated 2026-05-27.
Sponsored by Institut Paoli-CalmettesFull details on ClinicalTrials.gov → - recruitingPhase 2NCT05589818
Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radiation. Pati...
Listed by the study for Non-Small Cell Lung Cancer (NSCLC). Record updated 2026-06-15.
Sponsored by Icahn School of Medicine at Mount SinaiFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT07109726
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Listed by the study for Lung Squamous Cell Carcinoma. Record updated 2026-08-21.
Sponsored by Terremoto Biosciences Inc.Full details on ClinicalTrials.gov → - recruitingNCT06818149
Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
This study aims to investigate the clinical classification and outcome-related biomarkers of immune checkpoint inhibitor (ICI)-related myocarditis in patients with lung cancer.A total of 50 patients with ICI-related myocarditis will be enrolled, including 25 with severe/critic...
Listed by the study for Lung Cancer. Record updated 2025-02-10.
Sponsored by Shanghai Chest HospitalFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both p...
Listed by the study for Carcinoma, Non-Small-Cell Lung. Record updated 2026-08-24.
Sponsored by Astellas Pharma Global Development, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 1NCT06307249
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhib...
Listed by the study for Lung Cancer. Record updated 2024-03-12.
Sponsored by Lebanese UniversityFull details on ClinicalTrials.gov → - recruitingPhase 1NCT05979818
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combinati...
Listed by the study for Non Small Cell Lung Cancer. Record updated 2024-11-19.
Sponsored by Second Xiangya Hospital of Central South UniversityFull details on ClinicalTrials.gov → - recruitingPhase 2NCT07154290
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is ...
Listed by the study for Non Small Cell Lung Cancer. Record updated 2026-09-11.
Sponsored by Regeneron PharmaceuticalsFull details on ClinicalTrials.gov → - recruitingNANCT07042724
Exercise and Nutrition on Early-stage NSCLC Outcomes: the STARLighT Study
The general goal of the STARLighT study is to test whether a structured physical exercise and nutritional intervention significantly impacts clinical outcomes in patients with early-stage lung cancer. The main questions it aims to answer are: * Can structured physical exerci...
Listed by the study for Lung Cancer (NSCLC). Record updated 2025-06-29.
Sponsored by Universita di VeronaFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06946927
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally ad...
Listed by the study for NSCLC (Advanced Non-small Cell Lung Cancer). Record updated 2025-07-01.
Sponsored by JemincareFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-09-16. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this lung cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.